Export 503 results:
Autore [ Titolo(Desc)] Tipo Anno
Filtri: First Letter Of Last Name è Z  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Minute M, Patti G, Tornese G, Faleschini E, Zuiani C, Ventura A. Sirolimus Therapy in Congenital Hyperinsulinism: A Successful Experience Beyond Infancy. Pediatrics 2015;136(5):e1373-6.
di Iasio MGrazia, Norcio A, Melloni E, Zauli G. SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155. Invest New Drugs 2012;30(6):2403-6.
Agnoletto C, Melloni E, Casciano F, Rigolin GMatteo, Rimondi E, Celeghini C, Brunelli L, Cuneo A, Secchiero P, Zauli G. Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. Oncotarget 2014;5(12):4347-60.
Agostinis C, Bulla R, Tisato V, De Seta F, Alberico S, Secchiero P, Zauli G. Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells. Hum Reprod 2012;27(10):2941-7.
Zauli G, Celeghini C, Monasta L, Martinelli M, Luppi S, Gonelli A, Grill V, Ricci G, Secchiero P. Soluble TRAIL is present at high concentrations in seminal plasma and promotes spermatozoa survival. Reproduction 2014;148(2):191-8.
Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MGrazia, Lanza F, Secchiero P. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica 2012;97(11):1722-30.
Zanin V, Delbue S, Marcuzzi A, Tavazzi E, Del Savio R, Crovella S, Marchioni E, Ferrante P, Comar M. Specific protein profile in cerebrospinal fluid from HIV-1-positive cART-treated patients affected by neurological disorders. J Neurovirol 2012;18(5):416-22.
Savoia A, Kunishima S, De Rocco D, Zieger B, Rand ML, Pujol-Moix N, Caliskan U, Tokgoz H, Pecci A, Noris P, Srivastava A, Ward C, Morel-Kopp M-C, Alessi M-C, Bellucci S, Beurrier P, de Maistre E, Favier R, Hézard N, Hurtaud-Roux M-F, Latger-Cannard V, Lavenu-Bombled C, Proulle V, Meunier S, Négrier C, Nurden A, Randrianaivo H, Fabris F, Platokouki H, Rosenberg N, HadjKacem B, Heller PG, Karimi M, Balduini CL, Pastore A, Lanza F. Spectrum of the mutations in Bernard-Soulier syndrome. Hum Mutat 2014;35(9):1033-45.
Maschio M, Cozzi G, Sanabor D, Zennaro F, Gloria P, Barbi E. Splenomegaly as presentation of a wandering spleen. J Pediatr 2010;157(5):859.e1.
Zampieri S, Buratti E, Dominissini S, Montalvo ALisa, Pittis MGabriela, Bembi B, Dardis A. Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients' phenotypes. Eur J Hum Genet 2011;19(4):422-31.
Bernardi S, Secchiero P, Zauli G. State of art and recent developments of anti-cancer strategies based on TRAIL. Recent Pat Anticancer Drug Discov 2012;7(2):207-17.
Zauli G, Voltan R, Tisato V, Secchiero P. State of the art of the therapeutic perspective of sorafenib against hematological malignancies. Curr Med Chem 2012;19(28):4875-84.

Amministrazione Trasparente